 <h1>Seroquel Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>quetiapine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about quetiapine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Seroquel.</p><h2>In Summary</h2><p><b>Common side effects of Seroquel include:</b> asthenia, constipation, dizziness, drowsiness, headache, increased serum cholesterol, increased serum triglycerides, increased thyroid stimulating hormone level, and xerostomia. <b>Other side effects include:</b> abdominal pain, dyspepsia, increased serum alanine aminotransferase, orthostatic hypotension, pharyngitis, weight gain, and tachycardia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to quetiapine: oral tablet, oral tablet extended release</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet; Tablet, Extended Release)</p><p>Increased Mortality in Elderly Patients with Dementia-Related PsychosisElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Quetiapine fumarate is not approved for the treatment of patients with dementia-related psychosis.Suicidal Thoughts and BehaviorsIncreased risk of suicidal thoughts and behavior in children, adolescents and young adults taking antidepressants.Monitor for worsening and emergence of suicidal thoughts and behaviors.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, quetiapine (the active ingredient contained in Seroquel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking quetiapine:</p><p>
<i>More common</i>
</p><ul>
<li>Chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>sleepiness or unusual drowsiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blurred vision</li>
<li>changes in patterns and rhythms of speech</li>
<li>chest pain</li>
<li>cough</li>
<li>drooling</li>
<li>fever</li>
<li>inability to move the eyes</li>
<li>inability to sit still</li>
<li>increased blinking or spasms of the eyelid</li>
<li>lip smacking or puckering</li>
<li>loss of balance control</li>
<li>mask-like face</li>
<li>muscle aches</li>
<li>need to keep moving</li>
<li>painful or difficult urination</li>
<li>puffing of the cheeks</li>
<li>rapid or worm-like movements of the tongue</li>
<li>restlessness</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>shuffling walk</li>
<li>slowed movements</li>
<li>slurred speech</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sticking out of the tongue</li>
<li>stiffness of the arms or legs</li>
<li>sweating</li>
<li>swelling of the face, arms, hands, feet, or lower legs</li>
<li>swollen glands</li>
<li>trembling and shaking of the hands and fingers</li>
<li>trouble with breathing, speaking, or swallowing</li>
<li>uncontrolled chewing movements</li>
<li>uncontrolled movements of the arms and legs</li>
<li>uncontrolled twisting movements of the neck, trunk, arms, or legs</li>
<li>unusual bleeding or bruising</li>
<li>unusual facial expressions</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Dry, puffy skin</li>
<li>fast, pounding, or irregular heartbeat</li>
<li>loss of appetite</li>
<li>menstrual changes</li>
<li>unusual secretion of milk (in females)</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Aching or discomfort in the lower legs or sensation of crawling in the legs</li>
<li>agitation</li>
<li>bed-wetting</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>bluish lips or skin</li>
<li>chest discomfort</li>
<li>constipation</li>
<li>dark urine</li>
<li>decreased awareness or responsiveness</li>
<li>decreased urine output</li>
<li>depression</li>
<li>diarrhea</li>
<li>difficulty breathing</li>
<li>difficulty in passing urine (dribbling)</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>faintness</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>increased thirst</li>
<li>indigestion</li>
<li>irritability</li>
<li>joint or muscle pain</li>
<li>light-colored stools</li>
<li>loss of consciousness</li>
<li>lower back or side pain</li>
<li>muscle cramps, spasms, stiffness, or twitching</li>
<li>nausea</li>
<li>painful or prolonged erection of the penis</li>
<li>painful urination</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>severe constipation</li>
<li>severe sleepiness</li>
<li>severe vomiting</li>
<li>sore throat</li>
<li>stomach pain, continuing</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>unusual bleeding or bruising unusual drowsiness, dullness, or feeling of sluggishness</li>
<li>unusual weight gain or loss</li>
<li>upper right abdominal pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of quetiapine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abnormal vision</li>
<li>belching</li>
<li>decreased appetite</li>
<li>decreased strength and energy</li>
<li>heartburn</li>
<li>increased appetite</li>
<li>increased muscle tone</li>
<li>increased sweating</li>
<li>indigestion</li>
<li>sneezing</li>
<li>stomach discomfort or upset</li>
<li>stuffy or runny nose</li>
</ul><p>
<!-- end oral tablet, oral tablet extended release --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to quetiapine: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>IR Formulations: The most commonly reported side effects included somnolence, dry mouth, weight gain, elevated triglycerides, headache, and agitation.</p>
<p></p>
<p>XR/XL Tablets: The most commonly reported side effects included somnolence, dry mouth, and sedation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Somnolence (up to 57%), headache (up to 21%), dizziness (up to 19%), sedation (up to 18.3%), extrapyramidal symptoms (up to 12.9%)</p>
<p><b>Common</b> (1% to 10%): Akathisia, ataxia, balance disorder, dysarthria, dyskinesia, dyskinetic event, dystonic event, extrapyramidal disorder, hypersomnia, hypertonia, hypoesthesia, incoordination, lethargy, other extrapyramidal event, paresthesia, parkinsonism, restless legs syndrome, seizure, speech disorder, syncope, tardive dyskinesia, tremor</p>
<p><b>Uncommon</b> (0.1% to 1%): Amnesia, cerebrovascular accident, hemiplegia, hyperkinesia, involuntary movements, migraine, myoclonus, stupor, taste perversion, vertigo</p>
<p><b>Rare</b> (0.01% to 0.1%): Aphasia, cerebral ischemia, choreoathetosis, neuralgia, neuroleptic malignant syndrome (NMS), subdural hematoma</p>
<p><b>Frequency not reported</b>: Stroke</p>
<p><b>Postmarketing reports</b>: Cerebrovascular accident, retrograde amnesia</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Very common</b> (10% or more): Somnolence (up to 53%), sedation (up to 31.9%), dizziness (up to 18%), headache (up to 17.5%), extrapyramidal symptoms (up to 11.2%)</p>
<p><b>Common</b> (1% to 10%): Akathisia, disturbance in attention, dysarthria, dyskinetic event, dystonic event, hypersomnia, lethargy, mental impairment, migraine, other extrapyramidal event, paresthesia, parkinsonism, restless legs syndrome, sinus headache, syncope, tremor, vertigo</p>
<p><b>Uncommon</b> (0.1% to 1%): Seizure, tardive dyskinesia</p>
<p><b>Rare</b> (0.01% to 0.1%): NMS</p>
<p><b>Frequency not reported</b>: Akinesia, cerebrovascular adverse reactions, choreoathetosis, cognitive impairment, cogwheel rigidity, drooling, dyskinesia, dystonia, extrapyramidal disorder, hypertonia, hypokinesia, motor impairment, movement disorder, parkinsonian gait, psychomotor agitation, psychomotor hyperactivity, stroke</p>
<p><b>Postmarketing reports</b>: Cerebrovascular accident, retrograde amnesia<sup>[Ref]</sup></p><p>Somnolence usually occurred during the first 2 weeks and resolved with continued therapy.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain.  While these effects have been shown as a class effect, each agent has its own profile.</p>
<p></p>
<p>Hyperglycemia: Adults: In controlled clinical trials of 12 weeks or less, 2.4% of patients with normal (less than 100 mg/dL) fasting plasma glucose (FPG) had at least 1 FPG reading of 126 mg/dL or greater (vs. placebo 1.4%) during treatment.  For patients with baseline borderline to high FPG (100 mg/dL or higher), 11.7% had at least 1 FPG reading of 126 mg/dL or greater (vs. placebo, 11.8%).  In 2 longer-term trials, the mean change in blood glucose from baseline in patients treated with this drug (mean exposure 213 days; n=646) was 5 mg/dL (vs. placebo -0.05 mg/dL).  Among patients with major depressive disorder receiving the extended-release formulation of this drug, a FBG greater than 126 mg/dL occurred in 7%, 12%, and 6% of those receiving 150 mg, 300 mg, or placebo.  In a study of patients 10 to 17 years old with bipolar mania, the mean change in fasting glucose was 3.62 mg/dL (n=170).  No patients with a baseline fasting glucose level lower than 126 mg/dL had a treatment-emergent blood glucose level greater than 126 mg/dL.</p>
<p></p>
<p>Dyslipidemia: Across indications, adult patients who experienced shifts in total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol from baseline to clinically significant levels occurred in up to 18%, 22%, 6%, and 14% of patients receiving this drug compared with up to 7%, 16%, 5%, and 14% receiving placebo, respectively.  For pediatric patients, the shifts were up to 12%, 22%, 8%, and 15% compared to up to 3%, 13%, 5%, and 19% for this drug and placebo, respectively.</p>
<p></p>
<p>Weight gain: Logistic regression analysis has shown a positive dose response for weight gain.  Five to 10% of adult patients experienced a weight gain of 7% or greater (vs. up to 5% in placebo).  Among children and adolescents, a weight gain of 7% or greater occurred in 7% to 21% of patients receiving this drug compared with up to 7% in placebo patients.  Mean change in body weight was 1.7 to 2 kg in 3- to 6-week trials and 4.4 kg in 26-week trials.  These results were not adjusted for normal growth.<sup>[Ref]</sup></p><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Weight gain (up to 45%), elevated triglycerides (up to 23%), decreased fasting high-density lipoprotein (HDL) cholesterol (up to 18.3%), total cholesterol elevations (up to 16%), increased appetite (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Anorexia, blood glucose increased to hyperglycemic levels, thirst</p>
<p><b>Uncommon</b> (0.1% to 1%): Alcohol intolerance, alkaline phosphatase increased, dehydration, diabetes mellitus, exacerbation of pre-existing diabetes, hyperglycemia, hyperlipidemia, hypoglycemia, hyponatremia, weight loss</p>
<p><b>Rare</b> (0.01% to 0.1%): Gout, hypokalemia, metabolic syndrome, water intoxication</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Very common</b> (10% or more): Triglyceride elevations (up to 18%), total cholesterol elevations (up to 17%), increased appetite (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Blood glucose increased to hyperglycemic levels, decreased appetite, increased blood glucose, weight gain/weight increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus, exacerbation of pre-existing diabetes, hyponatremia</p>
<p><b>Rare</b> (0.01% to 0.1%): Metabolic syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Logistic regression analysis has shown a positive dose response for dyspepsia and abdominal pain.<sup>[Ref]</sup></p><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Dry mouth (up to 44%), vomiting (up to 10.8%), constipation (up to 10%), nausea (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, dysphagia, gastroenteritis, gastroesophageal reflux disease (GERD), stomach discomfort, stomatitis, tooth abscess</p>
<p><b>Uncommon</b> (0.1% to 1%): Fecal incontinence, flatulence, gastritis, gingivitis, gum hemorrhage, hemorrhoids, increased salivation, rectal hemorrhage, tongue edema, tooth caries, mouth ulceration</p>
<p><b>Rare</b> (0.01% to 0.1%): Abdomen enlarged, buccoglossal syndrome, glossitis, hematemesis, intestinal ileus, intestinal obstruction, melena, pancreatitis</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Very common</b> (10% or more): Dry mouth (up to 40%), nausea (up to 13.3%), constipation (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, dyspepsia, toothache, viral gastroenteritis, vomiting</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysphagia</p>
<p><b>Rare</b> (0.01% to 0.1%): Intestinal ileus, intestinal obstruction, pancreatitis<sup>[Ref]</sup></p><h3>Other</h3><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Asthenia (up to 17.6%), fatigue (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Accidental overdose, ear pain, fever, heaviness, mild asthenia, pain, pyrexia</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal gait, chills, malaise, tinnitus</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypothermia, deafness</p>
<p><b>Frequency not reported</b>: Falls, increased mortality</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Very common</b> (10% or more): Fatigue (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Ear pain, fall, mild asthenia, pyrexia, sluggishness</p>
<p><b>Rare</b> (0.01% to 0.1%): Hypothermia</p>
<p><b>Frequency not reported</b>: Increased mortality<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Agitation (up to 20%), discontinuation symptoms (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Abnormal dreams, aggression, anxiety, depression, insomnia, irritability, nightmares, suicidal behavior, suicidal ideation, suicide-related events, thinking abnormal</p>
<p><b>Uncommon</b> (0.1% to 1%): Apathy, bruxism, catatonic reaction, confusion, delusions, depersonalization, hallucinations, libido increased, manic reaction, paranoid reaction, psychosis, suicide attempt</p>
<p><b>Rare</b> (0.01% to 0.1%): Delirium, emotional lability, euphoria, libido decreased, neonatal withdrawal, sleep-related eating disorder, sleep talking, somnambulism and other related events, stuttering</p>
<p><b>Frequency not reported</b>: Drug withdrawal syndrome neonatal</p>
<p><b>Postmarketing reports</b>: Nocturnal enuresis</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Abnormal dreams, anxiety, confusional state, depression, discontinuation/withdrawal symptoms, disorientation, insomnia, irritability, libido decreased, nightmares, restlessness, schizophrenia, suicidal behavior, suicidal ideation, suicide-related events</p>
<p><b>Rare</b> (0.01% to 0.1%): Sleep-related eating disorder, sleep talking, somnambulism and related reactions</p>
<p><b>Frequency not reported</b>: Drug withdrawal syndrome neonatal</p>
<p><b>Postmarketing reports</b>: Nocturnal enuresis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents, including this drug, for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug treated patient than in the placebo treated patient.  The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  Similar results (i.e., increased risk of mortality with atypical antipsychotics) were reported in another meta-analysis involving elderly dementia patients that consisted of 15 randomized, placebo-controlled trials (n=3353) of 10 to 12 weeks in duration.  This drug should not be used to treat behavioral disorders in elderly patients with dementia.</p>
<p></p>
<p>An increased risk of mortality, possibly due to heart failure or sudden death, has been reported with the use of atypical antipsychotic agents in the treatment of behavioral disorders in the elderly patient with dementia.</p>
<p></p>
<p>The results of a large retrospective cohort study appear to indicate that atypical antipsychotic agents (e.g., clozapine, olanzapine, risperidone, this drug) increase the risk of venous thromboembolism in elderly patients; however, these events seem to be rare.</p>
<p></p>
<p>Blood pressure elevations described as systolic elevations of 20 mmHg or greater and diastolic elevations of 10 mmHg or greater were observed in 15.2% and 40.6% of children and adolescents, respectively.  A child with a history of hypertension experienced a hypertensive crisis.</p>
<p></p>
<p>QT intervals have not been systematically evaluated.  During clinical trials, persistent increases in QT intervals were not identified; however there have been postmarketing reports of QT prolongation in patients who overdosed on this drug, in patients with concomitant illness, and in patients taking drugs that are known to cause electrolyte imbalance or QT interval prolongation.<sup>[Ref]</sup></p><p>Immediate-Release (IR) Formulations:</p>
<p><b>Very common</b> (10% or more): Postural hypotension (up to 12.2%), tachycardia (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hypotension, hypertension, increased blood pressure, orthostatic hypotension, pallor, palpitations, peripheral edema, sinus tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Bradycardia, bundle branch block, cyanosis, deep thrombophlebitis, irregular pulse, QT interval prolonged, T wave abnormality, T wave inversion, vasodilation</p>
<p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, atrial fibrillation, atrioventricular (AV) block first degree, congestive heart failure, hand edema, increased QRS duration, ST abnormality, ST elevated, thrombophlebitis, T wave flattening, venous thromboembolism</p>
<p><b>Postmarketing reports</b>: Cardiomyopathy, myocarditis</p>
<p></p>
<p>Extended-Release (XR)/Prolonged-release (XL) Tablets:</p>
<p><b>Common</b> (1% to 10%): Heart rate increased, hypotension, increases in blood pressure, orthostatic hypotension, palpitations, peripheral edema, tachycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): Bradycardia, QT prolongation</p>
<p><b>Rare</b> (0.01% to 0.1%): Venous thromboembolism</p>
<p><b>Postmarketing reports</b>: Cardiomyopathy, myocarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>IR Formulations:</p>
<p><b>Very common</b> (10% or more): Decreased hemoglobin (Up to 11%)</p>
<p><b>Common</b> (1% to 10%): Decreased neutrophil count, eosinophils increased, leukopenia, neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, eosinophilia, hypochromic anemia, leukocytosis, lymphadenopathy, platelet count decreased, severe neutropenia, thrombocytopenia</p>
<p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, hemolysis</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Very common</b> (10% or more): Decreased hemoglobin (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Decreased neutrophil count, eosinophils increased, leukopenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anemia, neutropenia, platelet count decreased, thrombocytopenia</p>
<p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Cough, cough increased, dyspnea, epistaxis, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinus congestion, sinusitis, upper respiratory tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Asthma, pneumonia</p>
<p><b>Rare</b> (0.01% to 0.1%): Hiccup, hyperventilation</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Dyspnea, nasal congestion, nasopharyngitis, sinus congestion, sinusitis, upper respiratory tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhinitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Decreased total T3, decreased free T4, decreased total T4, hormone levels altered, hyperprolactinemia, hypothyroidism, increased thyroid stimulating hormone (TSH), serum prolactin elevations</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreased free T3</p>
<p><b>Rare</b> (0.01% to 0.1%): Gynecomastia, hyperthyroidism</p>
<p><b>Postmarketing reports</b>: Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Decreased free T4, decreased total T3, decreased total T4, elevations in serum prolactin, hyperprolactinemia, increased TSH</p>
<p><b>Uncommon</b> (0.1% to 1%): Decreased free T3, hypothyroidism</p>
<p><b>Very rare</b> (less than 0.01%): SIADH<sup>[Ref]</sup></p><p>In adults, dose-related decreases in thyroid hormone levels have been observed.  It appears that maximal reductions in total and free thyroxine (T4) occur in the first 6 weeks of treatment and are maintained without adaptation or progression during chronic therapy.  Upon therapy discontinuation, these effects mostly return to baseline values.  The mechanism by which this drug affects the thyroid axis is unclear.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Arthralgia, back pain, muscle rigidity, musculoskeletal stiffness, pain in extremity, twitching</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthritis, bone pain, leg cramps, neck pain, myasthenia, pathological fracture</p>
<p><b>Rare</b> (0.01% to 0.1%): Elevations in blood creatine phosphokinase</p>
<p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Arthralgia, back pain, muscle spasms, myalgia, neck pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Elevations in blood creatine phosphokinase</p>
<p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis</p>
<p><b>Frequency not reported</b>: Muscle rigidity, neck rigidity, nuchal rigidity<sup>[Ref]</sup></p><h3>Hepatic</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): ALT increased, AST increased, GGT increased</p>
<p><b>Rare</b> (0.01% to 0.1%): Hepatitis, jaundice</p>
<p><b>Postmarketing reports</b>: Cholestatic liver injury, hepatic failure/fatal hepatic failure, hepatic steatosis, mixed liver injury</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Elevations in ALT, elevations in GGT, transaminase elevations</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevations in AST</p>
<p><b>Rare</b> (0.01% to 0.1%): Hepatitis, jaundice</p>
<p><b>Postmarketing reports</b>: Cholestatic liver injury, hepatic failure/fatal hepatic failure, hepatic steatosis, mixed liver injury<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Acne, rash, sweating</p>
<p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions, contact dermatitis, ecchymosis, eczema, face edema, maculopapular rash, photosensitivity reaction, pruritus, seborrhea, skin ulcer</p>
<p><b>Rare</b> (0.01% to 0.1%): Exfoliative dermatitis, psoriasis, skin discoloration</p>
<p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome (SJS)</p>
<p><b>Frequency not reported</b>: Drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, toxic epidermal necrolysis (TEN)</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Hyperhidrosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions</p>
<p><b>Very rare</b> (less than 0.01%): SJS</p>
<p><b>Frequency not reported</b>: DRESS, erythema multiforme, TEN<sup>[Ref]</sup></p><h3>Immunologic</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Flu syndrome, infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Moniliasis</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Influenza, seasonal allergy<sup>[Ref]</sup></p><h3>Ocular</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Amblyopia, vision blurred</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal vision, blepharitis, conjunctivitis, dry eyes, eye pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Abnormality of accommodation, glaucoma</p>
<p><b>Postmarketing reports</b>: Cataract</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Vision blurred</p>
<p><b>Frequency not reported</b>: Oculogyration</p>
<p><b>Postmarketing reports</b>: Cataract<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>IR Formulations:</p>
<p><b>Common</b> (1% to 10%): Urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Abnormal ejaculation, amenorrhea, cystitis, dysmenorrhea, dysuria, female lactation, impotence, leukorrhea, metrorrhagia, orchitis, pelvic pain, sexual dysfunction, urinary frequency, urinary incontinence, urinary retention, vaginal hemorrhage, vaginal moniliasis, vaginitis, vulvovaginitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Breast swelling, galactorrhea, menstrual disorder, nocturia, polyuria, priapism</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Common</b> (1% to 10%): Pollakiuria</p>
<p><b>Uncommon</b> (0.1% to 1%): Sexual dysfunction, urinary retention</p>
<p><b>Rare</b> (0.01% to 0.1%): Breast swelling, galactorrhea, menstrual disorder, priapism<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>IR Formulations:</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction, angioedema</p>
<p></p>
<p>XR/XL Tablets:</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction, angioedema<sup>[Ref]</sup></p><h3>Renal</h3><p>IR Formulations:</p>
<p><b>Uncommon</b> (0.1% to 1%): Creatinine increased</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute kidney failure, glycosuria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. Seroquel XR (quetiapine)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Seroquel (quetiapine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>423 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: atypical antipsychotics</li>
<li>FDA Alerts (6)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Seroquel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Seroquel XR</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bipolar Disorder</li>
<li>Schizoaffective Disorder</li>
<li>Schizophrenia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to quetiapine: oral tablet, oral tablet extended release</i></p><h3>General</h3><p>IR Formulations: The most commonly reported side effects included somnolence, dry mouth, weight gain, elevated triglycerides, headache, and agitation.</p><p></p><p>XR/XL Tablets: The most commonly reported side effects included somnolence, dry mouth, and sedation.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Somnolence (up to 57%), headache (up to 21%), dizziness (up to 19%), sedation (up to 18.3%), extrapyramidal symptoms (up to 12.9%)</p><p><b>Common</b> (1% to 10%): Akathisia, ataxia, balance disorder, dysarthria, dyskinesia, dyskinetic event, dystonic event, extrapyramidal disorder, hypersomnia, hypertonia, hypoesthesia, incoordination, lethargy, other extrapyramidal event, paresthesia, parkinsonism, restless legs syndrome, seizure, speech disorder, syncope, tardive dyskinesia, tremor</p><p><b>Uncommon</b> (0.1% to 1%): Amnesia, cerebrovascular accident, hemiplegia, hyperkinesia, involuntary movements, migraine, myoclonus, stupor, taste perversion, vertigo</p><p><b>Rare</b> (0.01% to 0.1%): Aphasia, cerebral ischemia, choreoathetosis, neuralgia, neuroleptic malignant syndrome (NMS), subdural hematoma</p><p><b>Frequency not reported</b>: Stroke</p><p><b>Postmarketing reports</b>: Cerebrovascular accident, retrograde amnesia</p><p></p><p>XR/XL Tablets:</p><p><b>Very common</b> (10% or more): Somnolence (up to 53%), sedation (up to 31.9%), dizziness (up to 18%), headache (up to 17.5%), extrapyramidal symptoms (up to 11.2%)</p><p><b>Common</b> (1% to 10%): Akathisia, disturbance in attention, dysarthria, dyskinetic event, dystonic event, hypersomnia, lethargy, mental impairment, migraine, other extrapyramidal event, paresthesia, parkinsonism, restless legs syndrome, sinus headache, syncope, tremor, vertigo</p><p><b>Uncommon</b> (0.1% to 1%): Seizure, tardive dyskinesia</p><p><b>Rare</b> (0.01% to 0.1%): NMS</p><p><b>Frequency not reported</b>: Akinesia, cerebrovascular adverse reactions, choreoathetosis, cognitive impairment, cogwheel rigidity, drooling, dyskinesia, dystonia, extrapyramidal disorder, hypertonia, hypokinesia, motor impairment, movement disorder, parkinsonian gait, psychomotor agitation, psychomotor hyperactivity, stroke</p><p><b>Postmarketing reports</b>: Cerebrovascular accident, retrograde amnesia<sup>[Ref]</sup></p><p>Somnolence usually occurred during the first 2 weeks and resolved with continued therapy.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain.  While these effects have been shown as a class effect, each agent has its own profile.</p><p></p><p>Hyperglycemia: Adults: In controlled clinical trials of 12 weeks or less, 2.4% of patients with normal (less than 100 mg/dL) fasting plasma glucose (FPG) had at least 1 FPG reading of 126 mg/dL or greater (vs. placebo 1.4%) during treatment.  For patients with baseline borderline to high FPG (100 mg/dL or higher), 11.7% had at least 1 FPG reading of 126 mg/dL or greater (vs. placebo, 11.8%).  In 2 longer-term trials, the mean change in blood glucose from baseline in patients treated with this drug (mean exposure 213 days; n=646) was 5 mg/dL (vs. placebo -0.05 mg/dL).  Among patients with major depressive disorder receiving the extended-release formulation of this drug, a FBG greater than 126 mg/dL occurred in 7%, 12%, and 6% of those receiving 150 mg, 300 mg, or placebo.  In a study of patients 10 to 17 years old with bipolar mania, the mean change in fasting glucose was 3.62 mg/dL (n=170).  No patients with a baseline fasting glucose level lower than 126 mg/dL had a treatment-emergent blood glucose level greater than 126 mg/dL.</p><p></p><p>Dyslipidemia: Across indications, adult patients who experienced shifts in total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol from baseline to clinically significant levels occurred in up to 18%, 22%, 6%, and 14% of patients receiving this drug compared with up to 7%, 16%, 5%, and 14% receiving placebo, respectively.  For pediatric patients, the shifts were up to 12%, 22%, 8%, and 15% compared to up to 3%, 13%, 5%, and 19% for this drug and placebo, respectively.</p><p></p><p>Weight gain: Logistic regression analysis has shown a positive dose response for weight gain.  Five to 10% of adult patients experienced a weight gain of 7% or greater (vs. up to 5% in placebo).  Among children and adolescents, a weight gain of 7% or greater occurred in 7% to 21% of patients receiving this drug compared with up to 7% in placebo patients.  Mean change in body weight was 1.7 to 2 kg in 3- to 6-week trials and 4.4 kg in 26-week trials.  These results were not adjusted for normal growth.<sup>[Ref]</sup></p><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Weight gain (up to 45%), elevated triglycerides (up to 23%), decreased fasting high-density lipoprotein (HDL) cholesterol (up to 18.3%), total cholesterol elevations (up to 16%), increased appetite (up to 10%)</p><p><b>Common</b> (1% to 10%): Anorexia, blood glucose increased to hyperglycemic levels, thirst</p><p><b>Uncommon</b> (0.1% to 1%): Alcohol intolerance, alkaline phosphatase increased, dehydration, diabetes mellitus, exacerbation of pre-existing diabetes, hyperglycemia, hyperlipidemia, hypoglycemia, hyponatremia, weight loss</p><p><b>Rare</b> (0.01% to 0.1%): Gout, hypokalemia, metabolic syndrome, water intoxication</p><p></p><p>XR/XL Tablets:</p><p><b>Very common</b> (10% or more): Triglyceride elevations (up to 18%), total cholesterol elevations (up to 17%), increased appetite (up to 12%)</p><p><b>Common</b> (1% to 10%): Blood glucose increased to hyperglycemic levels, decreased appetite, increased blood glucose, weight gain/weight increased</p><p><b>Uncommon</b> (0.1% to 1%): Diabetes mellitus, exacerbation of pre-existing diabetes, hyponatremia</p><p><b>Rare</b> (0.01% to 0.1%): Metabolic syndrome<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Logistic regression analysis has shown a positive dose response for dyspepsia and abdominal pain.<sup>[Ref]</sup></p><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Dry mouth (up to 44%), vomiting (up to 10.8%), constipation (up to 10%), nausea (up to 10%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dyspepsia, dysphagia, gastroenteritis, gastroesophageal reflux disease (GERD), stomach discomfort, stomatitis, tooth abscess</p><p><b>Uncommon</b> (0.1% to 1%): Fecal incontinence, flatulence, gastritis, gingivitis, gum hemorrhage, hemorrhoids, increased salivation, rectal hemorrhage, tongue edema, tooth caries, mouth ulceration</p><p><b>Rare</b> (0.01% to 0.1%): Abdomen enlarged, buccoglossal syndrome, glossitis, hematemesis, intestinal ileus, intestinal obstruction, melena, pancreatitis</p><p></p><p>XR/XL Tablets:</p><p><b>Very common</b> (10% or more): Dry mouth (up to 40%), nausea (up to 13.3%), constipation (up to 11%)</p><p><b>Common</b> (1% to 10%): Diarrhea, dyspepsia, toothache, viral gastroenteritis, vomiting</p><p><b>Uncommon</b> (0.1% to 1%): Dysphagia</p><p><b>Rare</b> (0.01% to 0.1%): Intestinal ileus, intestinal obstruction, pancreatitis<sup>[Ref]</sup></p><h3>Other</h3><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Asthenia (up to 17.6%), fatigue (up to 14%)</p><p><b>Common</b> (1% to 10%): Accidental overdose, ear pain, fever, heaviness, mild asthenia, pain, pyrexia</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal gait, chills, malaise, tinnitus</p><p><b>Rare</b> (0.01% to 0.1%): Hypothermia, deafness</p><p><b>Frequency not reported</b>: Falls, increased mortality</p><p></p><p>XR/XL Tablets:</p><p><b>Very common</b> (10% or more): Fatigue (up to 14%)</p><p><b>Common</b> (1% to 10%): Ear pain, fall, mild asthenia, pyrexia, sluggishness</p><p><b>Rare</b> (0.01% to 0.1%): Hypothermia</p><p><b>Frequency not reported</b>: Increased mortality<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Agitation (up to 20%), discontinuation symptoms (up to 16%)</p><p><b>Common</b> (1% to 10%): Abnormal dreams, aggression, anxiety, depression, insomnia, irritability, nightmares, suicidal behavior, suicidal ideation, suicide-related events, thinking abnormal</p><p><b>Uncommon</b> (0.1% to 1%): Apathy, bruxism, catatonic reaction, confusion, delusions, depersonalization, hallucinations, libido increased, manic reaction, paranoid reaction, psychosis, suicide attempt</p><p><b>Rare</b> (0.01% to 0.1%): Delirium, emotional lability, euphoria, libido decreased, neonatal withdrawal, sleep-related eating disorder, sleep talking, somnambulism and other related events, stuttering</p><p><b>Frequency not reported</b>: Drug withdrawal syndrome neonatal</p><p><b>Postmarketing reports</b>: Nocturnal enuresis</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Abnormal dreams, anxiety, confusional state, depression, discontinuation/withdrawal symptoms, disorientation, insomnia, irritability, libido decreased, nightmares, restlessness, schizophrenia, suicidal behavior, suicidal ideation, suicide-related events</p><p><b>Rare</b> (0.01% to 0.1%): Sleep-related eating disorder, sleep talking, somnambulism and related reactions</p><p><b>Frequency not reported</b>: Drug withdrawal syndrome neonatal</p><p><b>Postmarketing reports</b>: Nocturnal enuresis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Collective data gathered from 17 placebo-controlled clinical studies (n=5106) involving the use of atypical antipsychotic agents, including this drug, for the treatment of behavioral disorders in the elderly patient with dementia showed a risk of death 1.6 to 1.7 times greater in the drug treated patient than in the placebo treated patient.  The average length of duration for the trials was 10 weeks with the cause of death in the majority of cases, though not all, reported as either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  Similar results (i.e., increased risk of mortality with atypical antipsychotics) were reported in another meta-analysis involving elderly dementia patients that consisted of 15 randomized, placebo-controlled trials (n=3353) of 10 to 12 weeks in duration.  This drug should not be used to treat behavioral disorders in elderly patients with dementia.</p><p></p><p>An increased risk of mortality, possibly due to heart failure or sudden death, has been reported with the use of atypical antipsychotic agents in the treatment of behavioral disorders in the elderly patient with dementia.</p><p></p><p>The results of a large retrospective cohort study appear to indicate that atypical antipsychotic agents (e.g., clozapine, olanzapine, risperidone, this drug) increase the risk of venous thromboembolism in elderly patients; however, these events seem to be rare.</p><p></p><p>Blood pressure elevations described as systolic elevations of 20 mmHg or greater and diastolic elevations of 10 mmHg or greater were observed in 15.2% and 40.6% of children and adolescents, respectively.  A child with a history of hypertension experienced a hypertensive crisis.</p><p></p><p>QT intervals have not been systematically evaluated.  During clinical trials, persistent increases in QT intervals were not identified; however there have been postmarketing reports of QT prolongation in patients who overdosed on this drug, in patients with concomitant illness, and in patients taking drugs that are known to cause electrolyte imbalance or QT interval prolongation.<sup>[Ref]</sup></p><p>Immediate-Release (IR) Formulations:</p><p><b>Very common</b> (10% or more): Postural hypotension (up to 12.2%), tachycardia (up to 11%)</p><p><b>Common</b> (1% to 10%): Hypotension, hypertension, increased blood pressure, orthostatic hypotension, pallor, palpitations, peripheral edema, sinus tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Bradycardia, bundle branch block, cyanosis, deep thrombophlebitis, irregular pulse, QT interval prolonged, T wave abnormality, T wave inversion, vasodilation</p><p><b>Rare</b> (0.01% to 0.1%): Angina pectoris, atrial fibrillation, atrioventricular (AV) block first degree, congestive heart failure, hand edema, increased QRS duration, ST abnormality, ST elevated, thrombophlebitis, T wave flattening, venous thromboembolism</p><p><b>Postmarketing reports</b>: Cardiomyopathy, myocarditis</p><p></p><p>Extended-Release (XR)/Prolonged-release (XL) Tablets:</p><p><b>Common</b> (1% to 10%): Heart rate increased, hypotension, increases in blood pressure, orthostatic hypotension, palpitations, peripheral edema, tachycardia</p><p><b>Uncommon</b> (0.1% to 1%): Bradycardia, QT prolongation</p><p><b>Rare</b> (0.01% to 0.1%): Venous thromboembolism</p><p><b>Postmarketing reports</b>: Cardiomyopathy, myocarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>IR Formulations:</p><p><b>Very common</b> (10% or more): Decreased hemoglobin (Up to 11%)</p><p><b>Common</b> (1% to 10%): Decreased neutrophil count, eosinophils increased, leukopenia, neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, eosinophilia, hypochromic anemia, leukocytosis, lymphadenopathy, platelet count decreased, severe neutropenia, thrombocytopenia</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis, hemolysis</p><p></p><p>XR/XL Tablets:</p><p><b>Very common</b> (10% or more): Decreased hemoglobin (up to 11%)</p><p><b>Common</b> (1% to 10%): Decreased neutrophil count, eosinophils increased, leukopenia</p><p><b>Uncommon</b> (0.1% to 1%): Anemia, neutropenia, platelet count decreased, thrombocytopenia</p><p><b>Rare</b> (0.01% to 0.1%): Agranulocytosis<sup>[Ref]</sup></p><h3>Respiratory</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Cough, cough increased, dyspnea, epistaxis, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinus congestion, sinusitis, upper respiratory tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Asthma, pneumonia</p><p><b>Rare</b> (0.01% to 0.1%): Hiccup, hyperventilation</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Dyspnea, nasal congestion, nasopharyngitis, sinus congestion, sinusitis, upper respiratory tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Rhinitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Decreased total T3, decreased free T4, decreased total T4, hormone levels altered, hyperprolactinemia, hypothyroidism, increased thyroid stimulating hormone (TSH), serum prolactin elevations</p><p><b>Uncommon</b> (0.1% to 1%): Decreased free T3</p><p><b>Rare</b> (0.01% to 0.1%): Gynecomastia, hyperthyroidism</p><p><b>Postmarketing reports</b>: Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Decreased free T4, decreased total T3, decreased total T4, elevations in serum prolactin, hyperprolactinemia, increased TSH</p><p><b>Uncommon</b> (0.1% to 1%): Decreased free T3, hypothyroidism</p><p><b>Very rare</b> (less than 0.01%): SIADH<sup>[Ref]</sup></p><p>In adults, dose-related decreases in thyroid hormone levels have been observed.  It appears that maximal reductions in total and free thyroxine (T4) occur in the first 6 weeks of treatment and are maintained without adaptation or progression during chronic therapy.  Upon therapy discontinuation, these effects mostly return to baseline values.  The mechanism by which this drug affects the thyroid axis is unclear.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Arthralgia, back pain, muscle rigidity, musculoskeletal stiffness, pain in extremity, twitching</p><p><b>Uncommon</b> (0.1% to 1%): Arthritis, bone pain, leg cramps, neck pain, myasthenia, pathological fracture</p><p><b>Rare</b> (0.01% to 0.1%): Elevations in blood creatine phosphokinase</p><p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Arthralgia, back pain, muscle spasms, myalgia, neck pain</p><p><b>Rare</b> (0.01% to 0.1%): Elevations in blood creatine phosphokinase</p><p><b>Very rare</b> (less than 0.01%): Rhabdomyolysis</p><p><b>Frequency not reported</b>: Muscle rigidity, neck rigidity, nuchal rigidity<sup>[Ref]</sup></p><h3>Hepatic</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): ALT increased, AST increased, GGT increased</p><p><b>Rare</b> (0.01% to 0.1%): Hepatitis, jaundice</p><p><b>Postmarketing reports</b>: Cholestatic liver injury, hepatic failure/fatal hepatic failure, hepatic steatosis, mixed liver injury</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Elevations in ALT, elevations in GGT, transaminase elevations</p><p><b>Uncommon</b> (0.1% to 1%): Elevations in AST</p><p><b>Rare</b> (0.01% to 0.1%): Hepatitis, jaundice</p><p><b>Postmarketing reports</b>: Cholestatic liver injury, hepatic failure/fatal hepatic failure, hepatic steatosis, mixed liver injury<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Acne, rash, sweating</p><p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions, contact dermatitis, ecchymosis, eczema, face edema, maculopapular rash, photosensitivity reaction, pruritus, seborrhea, skin ulcer</p><p><b>Rare</b> (0.01% to 0.1%): Exfoliative dermatitis, psoriasis, skin discoloration</p><p><b>Very rare</b> (less than 0.01%): Stevens-Johnson syndrome (SJS)</p><p><b>Frequency not reported</b>: Drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, toxic epidermal necrolysis (TEN)</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Hyperhidrosis</p><p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions</p><p><b>Very rare</b> (less than 0.01%): SJS</p><p><b>Frequency not reported</b>: DRESS, erythema multiforme, TEN<sup>[Ref]</sup></p><h3>Immunologic</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Flu syndrome, infection</p><p><b>Uncommon</b> (0.1% to 1%): Moniliasis</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Influenza, seasonal allergy<sup>[Ref]</sup></p><h3>Ocular</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Amblyopia, vision blurred</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal vision, blepharitis, conjunctivitis, dry eyes, eye pain</p><p><b>Rare</b> (0.01% to 0.1%): Abnormality of accommodation, glaucoma</p><p><b>Postmarketing reports</b>: Cataract</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Vision blurred</p><p><b>Frequency not reported</b>: Oculogyration</p><p><b>Postmarketing reports</b>: Cataract<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>IR Formulations:</p><p><b>Common</b> (1% to 10%): Urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Abnormal ejaculation, amenorrhea, cystitis, dysmenorrhea, dysuria, female lactation, impotence, leukorrhea, metrorrhagia, orchitis, pelvic pain, sexual dysfunction, urinary frequency, urinary incontinence, urinary retention, vaginal hemorrhage, vaginal moniliasis, vaginitis, vulvovaginitis</p><p><b>Rare</b> (0.01% to 0.1%): Breast swelling, galactorrhea, menstrual disorder, nocturia, polyuria, priapism</p><p></p><p>XR/XL Tablets:</p><p><b>Common</b> (1% to 10%): Pollakiuria</p><p><b>Uncommon</b> (0.1% to 1%): Sexual dysfunction, urinary retention</p><p><b>Rare</b> (0.01% to 0.1%): Breast swelling, galactorrhea, menstrual disorder, priapism<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>IR Formulations:</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction, angioedema</p><p></p><p>XR/XL Tablets:</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Very rare</b> (less than 0.01%): Anaphylactic reaction, angioedema<sup>[Ref]</sup></p><h3>Renal</h3><p>IR Formulations:</p><p><b>Uncommon</b> (0.1% to 1%): Creatinine increased</p><p><b>Rare</b> (0.01% to 0.1%): Acute kidney failure, glycosuria<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. "Product Information. Seroquel XR (quetiapine)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2>More about Seroquel (quetiapine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>423 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: atypical antipsychotics</li>
<li>FDA Alerts (6)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Seroquel &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Seroquel XR</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bipolar Disorder</li>
<li>Schizoaffective Disorder</li>
<li>Schizophrenia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>